Chemistry:Censavudine

Short description: Investigational new anti-HIV drug

Censavudine

Clinical data
Other names	4'-ethynylstavudine, festinavir
Legal status
Legal status	Investigational
Identifiers
IUPAC name 1-[(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2H-furan-2-yl]-5-methylpyrimidine-2,4-dione
CAS Number	634907-30-5
PubChem CID	3008897
ChemSpider	2278330
UNII	6IE83O6NGA
KEGG	D10550
ChEMBL	ChEMBL124363
NIAID ChemDB	209894
Chemical and physical data
Formula	C12H12N2O4
Molar mass	248.238 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@](O2)(CO)C#C
InChI InChI=1S/C12H12N2O4/c1-3-12(7-15)5-4-9(18-12)14-6-8(2)10(16)13-11(14)17/h1,4-6,9,15H,7H2,2H3,(H,13,16,17)/t9-,12+/m1/s1 Key:OSYWBJSVKUFFSU-SKDRFNHKSA-N

Censavudine (INN) (BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.

Renaming

Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir etc.).